Literature DB >> 27783538

Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.

Andrew B Rosenkrantz1, James S Babb1, Samir S Taneja1, Justin M Ream1.   

Abstract

Purpose To test the impact of existing Prostate Imaging Reporting and Data System (PI-RADS) version 2 (V2) decision rules, as well as of proposed adjustments to these decision rules, on detection of Gleason score (GS) 7 or greater (GS ≥7) prostate cancer. Materials and Methods Two radiologists independently provided PI-RADS V2 scores for the dominant lesion on 343 prostate magnetic resonance (MR) examinations. Diagnostic performance for GS ≥7 tumor was assessed by using MR imaging-ultrasonography fusion-targeted biopsy as the reference. The impact of existing PI-RADS V2 decision rules, as well as a series of exploratory proposed adjustments, on the frequency of GS ≥7 tumor detection, was evaluated. Results A total of 210 lesions were benign, 43 were GS 6, and 90 were GS ≥7. Lesions were GS ≥7 in 0%-4.1% of PI-RADS categories 1 and 2, 11.4%-27.1% of PI-RADS category 3, 44.4%-49.3% of PI-RADS category 4, and 72.1%-73.7% of PI-RADS category 5 lesions. PI-RADS category 4 or greater had sensitivity of 78.9%-87.8% and specificity of 75.5%-79.1 for detecting GS ≥7 tumor. The frequency of GS ≥7 tumor for existing PI-RADS V2 decision rules was 30.0%-33.3% in peripheral zone (PZ) lesions upgraded from category 3 to 4 based on dynamic contrast enhancement (DCE) score of positive; 50.0%-66.7% in transition zone (TZ) lesions upgraded from category 3 to 4 based on diffusion-weighted imaging (DWI) score of 5; and 71.7%-72.7% of lesions in both zones upgraded from category 4 to 5 based on size of 15 mm or greater. The frequency of GS ≥7 tumor for proposed adjustments to the decision rules was 30.0%-60.0% for TZ lesions upgraded from category 3 to 4 based on DWI score of 4; 33.3%-57.1% for TZ lesions upgraded from category 3 to 4 based on DCE score of positive when incorporating new criteria (unencapsulated sheetlike enhancement) for DCE score of positive in TZ; and 56.4%-61.9% for lesions in both zones upgraded from category 4 to 5 based on size of 10-14 mm. Other proposed adjustments yielded GS ≥7 tumor in less than 15% of cases for one or more readers. Conclusion Existing PI-RADS V2 decision rules exhibited reasonable performance in detecting GS ≥7 tumor. Several proposed adjustments to the criteria (in TZ, upgrading category 3 to 4 based on DWI score of 4 or modified DCE score of positive; in PZ or TZ, upgrading category 4 to 5 based on size of 10-14 mm) may also have value for this purpose. © RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2016        PMID: 27783538     DOI: 10.1148/radiol.2016161124

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  48 in total

1.  Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.

Authors:  Sonia Gaur; Stephanie Harmon; Lauren Rosenblum; Matthew D Greer; Sherif Mehralivand; Mehmet Coskun; Maria J Merino; Bradford J Wood; Joanna H Shih; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2018-05-07       Impact factor: 3.959

2.  Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.

Authors:  Vinay Prabhu; Andrew B Rosenkrantz; Ricardo Otazo; Daniel K Sodickson; Stella K Kang
Journal:  J Magn Reson Imaging       Date:  2019-01-10       Impact factor: 4.813

3.  A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).

Authors:  Sonia Gaur; Stephanie Harmon; Rajan T Gupta; Daniel J Margolis; Nathan Lay; Sherif Mehralivand; Maria J Merino; Bradford J Wood; Peter A Pinto; Joanna H Shih; Peter L Choyke; Baris Turkbey
Journal:  Acad Radiol       Date:  2018-04-25       Impact factor: 3.173

4.  PROSTATEx Challenges for computerized classification of prostate lesions from multiparametric magnetic resonance images.

Authors:  Samuel G Armato; Henkjan Huisman; Karen Drukker; Lubomir Hadjiiski; Justin S Kirby; Nicholas Petrick; George Redmond; Maryellen L Giger; Kenny Cha; Artem Mamonov; Jayashree Kalpathy-Cramer; Keyvan Farahani
Journal:  J Med Imaging (Bellingham)       Date:  2018-11-10

5.  [Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis].

Authors:  Li-Zhi Lei; Yi-Kai Xu; Mei-Rong Hou; Meng-Qi He
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

Review 6.  Future Perspectives and Challenges of Prostate MR Imaging.

Authors:  Baris Turkbey; Peter L Choyke
Journal:  Radiol Clin North Am       Date:  2017-12-09       Impact factor: 2.303

Review 7.  Arguments against using an abbreviated or biparametric prostate MRI protocol.

Authors:  Felipe B Franco; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2020-12

Review 8.  PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway.

Authors:  Anwar R Padhani; Jelle Barentsz; Geert Villeirs; Andrew B Rosenkrantz; Daniel J Margolis; Baris Turkbey; Harriet C Thoeny; François Cornud; Masoom A Haider; Katarzyna J Macura; Clare M Tempany; Sadhna Verma; Jeffrey C Weinreb
Journal:  Radiology       Date:  2019-06-11       Impact factor: 11.105

9.  Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Authors:  Frank-Jan H Drost; Daniël F Osses; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Monique J Roobol; Ivo G Schoots
Journal:  Cochrane Database Syst Rev       Date:  2019-04-25

10.  Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15 mm the best threshold?

Authors:  Julie Y An; Stephanie A Harmon; Sherif Mehralivand; Marcin Czarniecki; Clayton P Smith; Julie A Peretti; Bradford J Wood; Peter A Pinto; Peter L Choyke; Joanna H Shih; Baris Turkbey
Journal:  Abdom Radiol (NY)       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.